CLAIMS:

1. Use of a first amount of ornithine phenylacetate and a second amount of ornithine phenylacetate for the manufacture of a medicament for treating or ameliorating hyperammonemia in a patient in need thereof, wherein the medicament comprises a first amount of ornithine phenylacetate for administration during a first period of time and the second amount of ornithine phenylacetate for administration during a second period of time;

wherein the first amount of ornithine phenylacetate is from 10 g to 30 g, and the second amount of ornithine phenylacetate is less than the first amount of ornithine phenylacetate, and

wherein the first period of time is from 1 hour to 10 hours, and a total of the first period of time and the second period of time is from 18 hours to 36 hours.

2. The use of claim 1, wherein the first amount of ornithine phenylacetate is 20 g, and the first period of time is 6 hours.

3. The use of claim 1 or 2, wherein the second amount of ornithine phenylacetate is 15 g, and the second period of time is 18 hours, and wherein the second amount of ornithine phenylacetate is for administration immediately after the completion of the administration of the first amount of ornithine phenylacetate.

4. The use of any one of claims 1 to 3, wherein the first amount of ornithine phenylacetate or the second amount of ornithine phenylacetate is for intravenous infusion.

5. The use of any one of claims 1 to 4, wherein the medicament further comprises a third amount of ornithine phenylacetate for administration during a third period of time immediately following the completion of the administration of the second amount of ornithine phenylacetate, and wherein the third period of time is from 2 days to 10 days.

6. The use of claim 5, wherein the third period of time is 4 days.

7. The use of claim 5 or 6, wherein the third amount of ornithine phenylacetate for administration per day (24 hours) is the same or less than the second amount of ornithine phenylacetate.

8. The use of claim 7, wherein the third amount of ornithine phenylacetate for administration per day is 15 g.

9. The use of any one of claims 5 to 8, wherein the third amount of ornithine phenylacetate is for intravenous infusion.

10. The use of any one of claims 1 to 9, wherein the patient is also receiving standard of care.

11. Use of a first amount of ornithine phenylacetate and a second amount of ornithine phenylacetate for the manufacture of a medicament for treating or ameliorating hyperammonemia

in a patient in need thereof, the medicament comprises a first amount of ornithine phenylacetate for administration during a first period of time and a second amount of ornithine phenylacetate for administration during a second period of time;

wherein the patient in need of treatment of hyperammonemia is suffering from impaired renal function and has estimated glomerular filtration rate (eGFR) between 15 mL/min/1.73m^2 and 29 mL/min/1.73m^2; and wherein the first amount of ornithine phenylacetate is from 5 g to 20 g, and the second amount of ornithine phenylacetate is less than the first amount of ornithine phenylacetate, and wherein the medicament is for intravenous infusion, and

wherein the first period of time is from 1 hour to 10 hours and a total of the first period of time and the second period of time is from 18 hours to 36 hours.

12. The use of claim 11, wherein the first amount of ornithine phenylacetate is from 7.5 g to 15 g, and the first period of time is from 4 hours to 6 hours.

13. The use of claim 11 or 12, wherein the second amount of ornithine phenylacetate is from 7.5 g to 15 g, and the second period of time is from 12 hours to 18 hours, and wherein the second amount of ornithine phenylacetate is for administration immediately after the completion of the administration of the first amount of ornithine phenylacetate.

14. The use of any one of claims 11 to 13, wherein the medicament further comprises a third amount of ornithine phenylacetate for administration during a third period of time immediately following the completion of the administration of the second amount of ornithine phenylacetate, and wherein the third period of time is from 2 days to 10 days.

15. The use of claim 14, wherein the third period of time is from 3 days to 4 days.

16. The use of claim 14 or 15, wherein the third amount of ornithine phenylacetate administered per day (24 hours) is the same or less than the second amount of ornithine phenylacetate.

17. The use of claim 16, wherein the third amount of ornithine phenylacetate for administration per day is from 7.5 g to 15 g, by intravenous infusion.

18. The use of any one of claims 11 to 17, wherein the patient is also receiving standard of care.

19. The use of any one of claims 1 to 18, wherein the patient's serum ammonia level is ≥ 21 μmol/L.

20. The use of any one of claims 1 to 19, wherein the patient has cirrhosis.

21. The use of any one of claims 1 to 20, wherein the patient is at risk of hepatic encephalopathy or has had at least one episode of hepatic encephalopathy, or is hospitalized due to one or more hepatic encephalopathy episodes.

22. The use of any one of claims 1 to 21, wherein the patient has received at least 4 hours to 6 hours of standard of care prior to the administration of the first amount of ornithine phenylacetate.

23. The use of any one of claims 1 to 22, wherein ornithine phenylacetate is for administration as an aqueous solution comprising 200 mg/mL to 400 mg/mL ornithine phenylacetate.

24. The use of claim 23, wherein the aqueous solution of ornithine phenylacetate has a pH of at least 5.